T J Littlewood

Summary

Affiliation: Nuffield Orthopaedic Centre
Country: UK

Publications

  1. ncbi Erythropoietin for the treatment of anemia associated with hematological malignancy
    T J Littlewood
    Department of Haematology, Oxford Radcliffe NHS Trust, Oxford OX3 9DU, UK
    Hematol Oncol 19:19-30. 2001
  2. ncbi Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial
    T J Littlewood
    John Radcliffe Hospital, Oxford, United Kingdom
    J Clin Oncol 19:2865-74. 2001
  3. ncbi Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy
    T J Littlewood
    Department of Haematology, Oxford Radcliffe Hospital, Oxford, UK
    Front Radiat Ther Oncol 37:34-7. 2002
  4. ncbi Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
    J Boultwood
    Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Hematol 61:5-9. 1999
  5. ncbi Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
    B E Shaw
    Department of Haematology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Bone Marrow Transplant 42:783-9. 2008
  6. ncbi The impact of hemoglobin levels on treatment outcomes in patients with cancer
    T J Littlewood
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Semin Oncol 28:49-53. 2001
  7. ncbi Is normalising haemoglobin in patients with CKD harmful and if so, why?
    T J Littlewood
    Department of Haematology, Cancer and Haematology Centre, Churchill Hospital, Old Rd, Oxford OX37LJ, UK
    J Ren Care 35:25-8. 2009
  8. ncbi Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML
    R K Malladi
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Bone Marrow Transplant 43:709-15. 2009
  9. ncbi The investigation and treatment of secondary anaemia
    Sarah L Davis
    Department of Haematology, Cancer and Haematology Centre, Oxford Radcliffe Hospitals, Headington, Oxford, OX3 7LJ, United Kingdom
    Blood Rev 26:65-71. 2012
  10. ncbi Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma
    T J Littlewood
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Bone Marrow Transplant 40:1147-55. 2007

Collaborators

Detail Information

Publications17

  1. ncbi Erythropoietin for the treatment of anemia associated with hematological malignancy
    T J Littlewood
    Department of Haematology, Oxford Radcliffe NHS Trust, Oxford OX3 9DU, UK
    Hematol Oncol 19:19-30. 2001
    ..A recent study also suggests that improving the hemoglobin level may improve the patients' prognosis but this finding needs to be confirmed...
  2. ncbi Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial
    T J Littlewood
    John Radcliffe Hospital, Oxford, United Kingdom
    J Clin Oncol 19:2865-74. 2001
    ..The study also explored a possible relationship between increased hemoglobin and survival...
  3. ncbi Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy
    T J Littlewood
    Department of Haematology, Oxford Radcliffe Hospital, Oxford, UK
    Front Radiat Ther Oncol 37:34-7. 2002
  4. ncbi Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
    J Boultwood
    Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Hematol 61:5-9. 1999
    ..These data show that a marked reduction in telomere length is associated with disease progression in CML...
  5. ncbi Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
    B E Shaw
    Department of Haematology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Bone Marrow Transplant 42:783-9. 2008
    ..014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant...
  6. ncbi The impact of hemoglobin levels on treatment outcomes in patients with cancer
    T J Littlewood
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Semin Oncol 28:49-53. 2001
    ..Recent studies have suggested that increasing hemoglobin levels with recombinant human erythropoietin (r-HuEPO, epoetin alfa) have resulted in better outcomes following radiotherapy, chemotherapy, and the combined-treatment modality...
  7. ncbi Is normalising haemoglobin in patients with CKD harmful and if so, why?
    T J Littlewood
    Department of Haematology, Cancer and Haematology Centre, Churchill Hospital, Old Rd, Oxford OX37LJ, UK
    J Ren Care 35:25-8. 2009
    ..0 g/dl. The mechanism for this increased risk is uncertain...
  8. ncbi Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML
    R K Malladi
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Bone Marrow Transplant 43:709-15. 2009
    ..02). In conclusion, alemtuzumab has a beneficial effect by reducing chronic GVHD without affecting overall survival. Further studies are warranted before alemtuzumab can be recommended as standard in RIC allografts for AML...
  9. ncbi The investigation and treatment of secondary anaemia
    Sarah L Davis
    Department of Haematology, Cancer and Haematology Centre, Oxford Radcliffe Hospitals, Headington, Oxford, OX3 7LJ, United Kingdom
    Blood Rev 26:65-71. 2012
    ..Finally, the management of a patient with ACD is discussed including erythropoiesis stimulating agents (ESAs), intravenous iron and future therapies...
  10. ncbi Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma
    T J Littlewood
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Bone Marrow Transplant 40:1147-55. 2007
    ..The clinical value of these laboratory findings is uncertain and the role of these agents after high-dose chemotherapy remains a subject for debate...
  11. ncbi Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Department of Cellular Science, John Radcliffe Hospital, Oxford, UK
    Blood 96:358-61. 2000
    ..The measurement of diagnostic TRA may prove to be clinically important in the selection of patients at high risk of disease transformation in CML...
  12. ncbi A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in
    G Jackson
    Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
    Br J Haematol 112:127-37. 2001
    ..It is therefore an important advance in developing new treatment options for these patients...
  13. ncbi Treatment of myelodysplasia with oral cyclosporin
    W Atoyebi
    Department of Haematology, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Clin Lab Haematol 24:211-4. 2002
    ..We suggest further therapeutic trials of CSA in MDS, selecting patients on the basis of in vitro studies that predict an immunological basis for their disease, to assess its efficacy in prolonging survival...
  14. ncbi The use of intravenous iron in patients with cancer-related anaemia
    T J Littlewood
    Department of Haematology, Oxford Radcliffe NHS Trust, Oxford, UK
    Br J Haematol 141:751-6. 2008
    ..The data supporting the efficacy of intravenous iron instead of oral iron in this setting are increasingly persuasive but larger randomised trials are needed before definitive recommendations are made...
  15. ncbi Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer
    D J Propper
    ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK
    Br J Cancer 82:1776-82. 2000
    ..However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen. This could be related to drug resistance rather than a failure to enhance cytotoxicity...
  16. ncbi Severe haemolysis after an ABO unmatched kidney transplant - a nonsecretor transplanted from a donor with high anti-A titre
    A J Sternberg
    Department of Haematology, John Radcliffe Hospital, Headington, Oxford Department of Surgery, Renal Transplant Unit, Churchill Hospital, Headington, Oxford, UK
    Transfus Med 10:87-9. 2000
    ..We discuss the risk factors for developing haemolysis in an ABO unmatched organ transplant and explore the possible relevance of such high donor antibody titre to recipients who are nonsecretors...
  17. ncbi Paraneoplastic pemphigus: an association with fludarabine?
    C Gooptu
    Department of Dermatology, The Oxford Radcliffe Hospital, Oxford, UK
    Br J Dermatol 144:1255-61. 2001
    ....